Home
About us
Editorial board
Ahead of print
Browse Articles
Search
Submit article
Instructions
Subscribe
Contacts
Login
Advanced Search
Users Online: 1478
» Articles published in the past year
To view other articles click corresponding year from the navigation links on the left side.
All
|
Case Report
|
Case Reports
|
Editorial
|
Erratum
|
Letter To Editor
|
Letters to Editor
|
Mini Review
|
Notice of Retraction
|
Original Article
|
Original Articles
|
Review Article
|
Review Articles
|
Short Communication
|
Short Communications
|
Systematic Review
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Show all abstracts
Show selected abstracts
Export selected to
Add to my list
Short Communication:
Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies
Masoud Etemadifar, Ramin Sami, Mehri Salari, Nahad Sedaghat, Amirhossein Akhavan Sigari, Ali Aghababaei, Mohammadreza Najafi, Donya Sheibani Tehrani
J Res Med Sci
2021, 26:85 (30 September 2021)
DOI
:10.4103/jrms.JRMS_1047_20
Background:
With the spread of COVID-19, treatment of diseases such as multiple sclerosis (MS) should be resumed with caution due to the disease-modifying therapies (DMTs) used in this subset of patients and the immunoregulatory effects of these drugs. We aim to assess the outcome of COVID-19 infection in MS patients receiving DMTs.
Materials and Methods:
This is a cross-sectional study involving 45 COVID-19-infected patients previously diagnosed with MS. The data regarding their MS status and the type of DMT taken by the patients were extracted from the Isfahan MS Institute registry and were summarized. Diagnosis of MS was based on the 2017 McDonald Criteria, and the diagnosis of COVID-19 was based on computed tomography scan and polymerase chain reaction of nasopharyngeal swabs.
Results:
Out of the 45 MS patients infected with COVID-19, 5 had unfavorable outcomes. Two patients deceased and the other three had persistent respiratory complications on the 4-week follow-up visit. Hypertension, diabetes, seizures, and rheumatoid arthritis were among the comorbidities that the patients reported. Both patients who died received rituximab as part of their MS treatment. All other patients recovered completely.
Conclusion:
Each different drug category may possess a distinct risk for infection, therefore until robust evidence are available, the safest drug should be utilized or the therapy should be postponed, if possible, to minimize patient risk. Disease-modifying therapy use in MS patients should be cautiously applied as their effect on COVID-19 infection prognosis is not yet studied.
[ABSTRACT]
[HTML Full text]
[PDF]
[Mobile Full text]
[EPub]
[Sword Plugin for Repository]
Beta
Short Communication:
Malus domestica
reduces chemotherapy-induced nausea and vomiting: A randomized double-blind placebo-controlled clinical trial
Sharareh Darvishpour, Razieh Avan, Mohammad Azadbakht, Monireh Maham, Jafar Akbari, Ghasem Janbabaei, Ehsan Zaboli, Ali Reza Amirabadizadeh, Ebrahim Salehifar
J Res Med Sci
2021, 26:72 (30 September 2021)
DOI
:10.4103/jrms.JRMS_833_20
Background:
Chemotherapy-induced nausea and vomiting (CINV) is considered as the most common complications of chemotherapy which has a detrimental influence on the quality of life of patients with cancer. We assessed the efficacy of Apple (
Malus domestica
) syrup for reducing CINV.
Materials and Methods:
This study was a randomized, double-blind, placebo-controlled trial carried out in a Hematooncology Clinic affiliated to Mazandaran University of Medical Sciences, Sari, Iran (from October 2017 to August 2018). Subjects were randomly allocated to receive apple syrup or placebo along with their previous antiemetic treatment and chemotherapy regimen, three times a day. Thirty-four patients received apple syrup (
n
= 16) or placebo (
n
= 18). Statistical analysis was conducted using SPSS software Version 21
®
(SPSS Inc., Chicago, IL, USA). A
P
< 0.05 indicated statistical significance.
Results:
Both acute and delayed nausea grades were significantly lower in
M. domestica
syrup in comparison to placebo syrup (
P
= 0.001 and 0.001, respectively). The duration of nausea (
P
= 0.04) was lower in intervention group compared to placebo group.
Conclusion:
These findings demonstrated that
M. domestica
syrup can reduce the severity and duration of nausea in cancer patients who received chemotherapy.
[ABSTRACT]
[HTML Full text]
[PDF]
[Mobile Full text]
[EPub]
[Sword Plugin for Repository]
Beta
Short Communication:
Ventilator Mode Finder: An Android application to find equivalent of a mode on different ventilators
Mahmoud Saghaei
J Res Med Sci
2021, 26:70 (30 September 2021)
DOI
:10.4103/jrms.JRMS_1358_20
There are hundreds of ventilator modes on different ventilators. Despite different names, many are similar in functions and options. Educational institutions only teach a limited collection of ventilator modes of a few numbers of models; therefore, graduates may have substantial difficulties encountering new ventilator models with unfamiliar mode names on them. In this article, an Android application for finding similar modes on different ventilators is presented. The aim is to help an intensive care practitioner to easily find a familiar mode on a new ventilator.
[ABSTRACT]
[HTML Full text]
[PDF]
[Mobile Full text]
[EPub]
[Sword Plugin for Repository]
Beta
Advanced Search
Month wise articles
Figures next to the month indicate the number of articles in that month
2023
February
[
2
]
2022
October
[
1
]
September
[
1
]
August
[
1
]
July
[
1
]
June
[
2
]
May
[
1
]
April
[
1
]
February
[
1
]
2021
November
[
2
]
September
[
3
]
July
[
2
]
June
[
1
]
2020
September
[
1
]
May
[
1
]
March
[
1
]
February
[
3
]
2019
December
[
1
]
August
[
1
]
June
[
1
]
April
[
1
]
March
[
1
]
February
[
1
]
January
[
1
]
2018
November
[
2
]
October
[
2
]
September
[
1
]
March
[
1
]
2017
December
[
1
]
June
[
1
]
Sitemap
|
What's New
Feedback
|
Copyright and Disclaimer
|
Privacy Notice
© Journal of Research in Medical Sciences | Published by Wolters Kluwer -
Medknow
Online since 9
th
February, 2015